Table 2.

Effect of PI3K Pathway Inhibitors on ABT-737 GI₅₀.

Cell Line	Treatment	ABT-737 GI50 (µM ± 95% CI)	Significance*
HCT116	DMSO	4.95 (4.15–5.90)
	2 µM PI-103	3.33 (2.88–3.84)	0.0268
	2 µM GDC0941	2.73 (2.54–2.93)	0.0036
	1 µM AKTi1/2	4.32 (4.17–4.46)	0.2092
	1 µM MK2206	4.06 (3.72–4.43)	0.1189
	10 nM rapamycin	6.19 (5.77–6.64)	0.0821
	2 µM KU0063794	6.57 (6.10–7.07)	0.0441
SW620	DMSO	16.9 (15.4–18.5)
	2 µM PI-103	3.15 (2.45–4.05)	0.0002
	2 µM GDC0941	6.09 (3.10–11.9)	0.0424
	1 µM AKTi1/2	14.5 (11.4–18.5)	0.3140
	1 µM MK2206	20.0 (10.6–37.6)	0.6317
	10 nM rapamycin	15.3 (12.8–18.4)	0.4049
	2 µM KU0063794	16.4 (12.9–20.8)	0.8369

^*Two-tailed unpaired t test versus DMSO-treated GI₅₀ for same cell line.